Document:

AMENDMENT NO

AMENDMENT

 TO

 ASSET PURCHASE AGREEMENT

This Amendment to the Asset Purchase Agreement (“Amendment”), by and between Global Sports Edge, Inc., Winning Edge International, Inc., Wayne Allyn Root and Betbrokers plc, and dated June 27, 2007, is entered into on this 31st day of August, 2007, by and between Global Sports Edge, Inc., Winning Edge International, Inc., Wayne Allyn Root and Betbrokers plc.

PREMISES:

A.     On June 27, 2007, the parties entered into an Asset Purchase Agreement (the “Agreement”).

B.      The parties desire to amend Section 1.02, Consideration and set the buyers price per share price.

C.   The parties desire to amend Section 1.04 of the Agreement to extend the closing deadline.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants of the parties, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

1.   Consideration and Price per Share.  The second sentence of Section 1.02 of the Agreement is hereby amended by replacing it with the following two sentences:  Solely for purposes of this Agreement, the value of the shares of Buyer’s stock shall be determined by the higher of (i) the average of the closing bid price on the five consecutive trading days prior to Closing, or (ii) 5.00 pence.   For purposes of valuing Buyer's stock in United States Dollars, it is agreed an exchange rate of $2.02 per British pound will be used.          

2.   Closing Deadline Extended.  Section 1.04 of the Agreement is hereby amended in its entirety to read as follows:

              

1.04 Closing and Parties.  The Closing contemplated hereby shall be held at a mutually agreed upon time and place (the “Closing Date”) but no later than September 14, 2007, or on such date that all required corporate action has been accomplished including any shareholder approval required by Seller’s parent corporation, Winning Edge.  The Closing may be accomplished by wire, express mail, overnight courier, conference telephone call or as otherwise agreed to by the respective parties or their duly authorized representatives.

3.   Other Inconsistent Provisions Hereby Amended.   Any other provisions of the Agreement  which are inconsistent with the terms of Sections 1 and 2 of this Amendment described above, shall be deemed to be amended consistent therewith.  All other terms and conditions of the Agreement shall remain unchanged and in full force and effect.

4.     Ratification.

Except as expressly amended hereby, the terms of the Agreement are hereby ratified and approved as originally written. 

5.     Counterparts.   This Amendment may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.

Capitalized terms not otherwise defined herein have the meanings given to such terms in the above referenced Asset Purchase Agreement.

IN WITNESS WHEREOF, the corporate parties hereto have caused this Agreement to be executed by their respective officers, hereunto duly authorized, as of the date first above written.

SELLER:

BUYER:

Global Sports Edge, Inc.

Betbrokers PLC

            A Delaware Corporation

A United Kingdom Corporation

By:__/s/___________________________

By:___/s/_________________________

     Wayne Allyn Root, CEO

     Wayne Lochner, Chairman

PARENT CORPORATION OF SELLER:

Winning Edge International, Inc.

By:__/s/___________________________

     ___/s/_________________________

      Name: Wayne Allyn Root

     Wayne Allyn Root

      Title: CEOFiled by Bowne Pure Compliance

 

Exhibit 10.1

SEPARATION AGREEMENT

This Separation Agreement (“Agreement”), dated as of September 6, 2007, is made by and among Integra LifeSciences
Holdings Corporation, a Delaware corporation (the “Company”), and Maureen B. Bellantoni (“Bellantoni”).

WHEREAS, the Company and Bellantoni are parties to that certain 2006 Employment Agreement, dated as of January 10,
2006, which sets forth the terms of Bellantoni’s employment by the Company (the “Employment Agreement”);

WHEREAS, pursuant to that certain Performance Stock Agreement, dated as of January 10, 2006, by and between the
Company and Bellantoni (the “Performance Stock Agreement”), the Company granted Bellantoni, under the Integra
LifeSciences Holdings Corporation 2003 Equity Incentive Plan (the “Plan”), the right to receive 10,000 shares of
Performance Stock (as defined in the Performance Stock Agreement) upon the satisfaction of certain performance goals
and other conditions set forth in the Performance Stock Agreement;

WHEREAS, pursuant to that certain Restricted Stock Agreement, dated as of April 2, 2007, by and between the
Company and Bellantoni (the “Restricted Stock Agreement”), the Company issued to Bellantoni 4,366 shares of restricted
common stock of the Company (the “Restricted Stock”) under the Plan; and

WHEREAS, the Company and Bellantoni desire to specify the terms of Bellantoni’s resignation from her positions as
Executive Vice President and Chief Financial Officer of the Company, and as an officer, director and employee of the
Company, and to provide for the termination of the Employment Agreement.

NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises contained herein, and for other
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and Bellantoni
(collectively, the “Parties”) hereby agree as follows:

1. RESIGNATION; TERMINATION OF EMPLOYMENT AGREEMENT

1.1. Resignation. Bellantoni hereby tenders, and the Company hereby accepts, Bellantoni’s resignations
from (a) her positions as Executive Vice President and Chief Financial Officer of the Company and as an officer,
director and employee of the Company, and (b) her positions as an officer, director and employee of any and all
subsidiaries and affiliates of the Company, in each case effective as of the close of business on September 6, 2007
(the “Termination Date”). Notwithstanding anything contained herein or in the Employment Agreement, Bellantoni’s
resignation hereunder shall not be deemed a resignation for “Good Reason” for purposes of, and as defined in, the
Employment Agreement. No later than the Termination Date, Bellantoni shall return to the Company all Company property
in her possession, including without limitation, keys, building access cards, identification cards, credit cards,
telephone calling cards, computer hardware and software, cellular and portable telephone

 

5

 

equipment, personal digital assistant (PDA) devices, combinations to safes, manuals, books, notebooks, financial
statements, reports and other documents.

1.2. Termination of Employment Agreement. Effective as of the Termination Date, Bellantoni’s employment
with the Company shall terminate and the Employment Agreement shall automatically terminate and be of no further force
or effect, and the Company shall have no further obligations thereunder. Notwithstanding the foregoing, the provisions
of Section 15 (Restrictive Covenants) of the Employment Agreement shall survive the termination of Bellantoni’s
employment and the termination of the Employment Agreement.

1.3. Separation Payments. Subject to Bellantoni’s execution, delivery and non-revocation of the Release
(as defined below) and subject to Bellantoni’s continued compliance with the Restrictive Covenants, the Company shall
provide the following payments and benefits to Bellantoni:

(i) the Company shall pay Bellantoni a lump-sum cash payment in an amount equal to $325,000 as soon as
practicable following the Termination Date (but in no event later than the first business day of the month
following the Termination Date); and

(ii) the Company shall maintain and provide to Bellantoni, at no cost to Bellantoni, for a period ending
at the earliest of (a) the first anniversary of the Termination Date, (b) the date of Bellantoni’s full-time
employment by another employer, or (c) Bellantoni’s death, continued participation in all group life, health,
accident and disability insurance plans in which Bellantoni would have been entitled to participate had her
employment with Company continued throughout such period; provided that such participation is not prohibited
by the terms of the plan or by the Company for legal reasons; provided, further, that in the event Bellantoni
elects to continue health care coverage in accordance with COBRA, the company will pay the COBRA cost of the
Company’s health plan for such period.

1.4. Performance Stock. Bellantoni hereby acknowledges and agrees that, in accordance with the
Performance Stock Agreement, as a result of the termination of her employment with the Company prior to the end of the
performance period for the Performance Stock, her right to receive any shares represented by the Performance Stock
shall terminate as of the Termination Date and all of her right, title and interest in the Performance Stock shall
thereupon be forfeited.

1.5. Restricted Stock. Bellantoni hereby acknowledges and agrees that, in accordance with the Restricted
Stock Agreement, all of her right, title and interest in the shares of Restricted Stock that have not vested as of her
termination of employment shall lapse and be forfeited as of the Termination Date, and all such shares shall thereupon
automatically be surrendered to the Company without consideration. The Parties acknowledge and agree that as of the
Termination Date, none of the shares of the Restricted Stock have vested.

 

6

 

2. GENERAL RELEASE.

2.1. General Release. Bellantoni agrees that, no later than twenty-one (21) days after the Termination
Date, she shall execute and deliver to the Company a release of claims in the form attached hereto as Exhibit A (the
“Release”), which Release shall become effective seven days after execution by Bellantoni. If Bellantoni decides to
revoke the release during such seven day period, she must send a written statement of revocation, by certified mail,
and postmarked no later than seven days after the date on which she signs the Release to the Company at the notice
address set forth below. Notwithstanding this Section 2.1, it shall be a condition to Bellantoni’s right to receive
the payments and benefits set forth in Section 1.3 above that Bellantoni execute, deliver to the Company and not revoke
the Release.

3. RESTRICTIVE COVENANTS

3.1. Reaffirmation of Prior Agreements. Bellantoni hereby acknowledges and agrees that she is bound by
certain non-compete, confidentiality, non-solicitation and other restrictive covenants set forth in Section 15 of the
Employment Agreement. Notwithstanding anything contained in this Agreement, Bellantoni hereby reaffirms the covenants
and provisions set forth in Section 15 of the Employment Agreement and acknowledges and agrees that the provisions of
Section 15 of the Employment Agreement shall survive the termination of Bellantoni’s employment with the Company and
the termination of the Employment Agreement, and shall remain in full force and effect.

3.2. Non-Disparagement. Bellantoni agrees that she will not make any statement, publicly or privately,
to any individual or entity, including, without limitation, clients, customers, employees, financial or credit
institutions, which could reasonably be expected to disparage the Company, any of its affiliates or any of their
respective employees, officers or directors.

3.3. Breach of Covenants. Bellantoni acknowledges that a breach by her of any of the covenants or
restrictions contained, reaffirmed or referenced herein (collectively, the “Restrictive Covenants”) will cause
irreparable damage to the Company, the exact amount of which will be difficult to ascertain, and that the remedies at
law for any such breach will be inadequate in whole or in part. Accordingly, Bellantoni agrees that if she breaches or
attempts to breach any such covenants or restrictions, the Company shall be entitled to, without limitation, temporary
or permanent injunctive relief with respect to any such breach or attempted breach (in addition to any other remedies,
at law or in equity, as may be available to the Company), without posting bond or other security. In the event that
the Company is required to enforce any of its rights under this Section 3, Bellantoni shall be obligated to reimburse
the Company for all reasonable costs and expenses, including reasonable attorneys’ fees, incurred by the Company in
connection with the enforcement of its rights hereunder.

 

7

 

4. DISPUTE RESOLUTION

4.1. Arbitration. Except as set forth in Section 3.3 above, any disagreement, dispute, controversy or
claim arising out of or relating to this Agreement or the interpretation of this Agreement or any arrangements relating
to this Agreement or contemplated in this Agreement or the breach, termination or invalidity thereof shall be settled
by final and binding arbitration administered by JAMS/Endispute in Princeton, New Jersey in accordance with the
then-existing JAMS/Endispute Arbitration Rules and Procedures for Employment Disputes. In the event of such an
arbitration proceeding, the Company and Bellantoni shall select a mutually acceptable neutral arbitrator from among the
JAMS/Endispute panel of arbitrators. In the event that Bellantoni and the Company cannot agree on an arbitrator, the
Administrator of JAMS/Endispute will appoint an arbitrator. Neither Bellantoni nor the Company nor the arbitrator
shall disclose the existence, content, or results of any arbitration hereunder without the prior written consent of the
Parties. Except as provided herein, the Federal Arbitration Act shall govern the interpretation, enforcement and all
proceedings. The arbitrator shall apply the substantive law (and the law of remedies, if applicable) of the state of
New Jersey, or federal law, or both, as applicable, and the arbitrator is without jurisdiction to apply any different
substantive law. Judgment upon any arbitration award may be entered in any court having jurisdiction thereof.

4.2. Waiver of Jury Trial. By submitting a dispute to arbitration, the Parties understand that they will
not enjoy the benefits of a jury trial. Accordingly, the Parties expressly waive the right to a jury trial.

4.3. Nonexclusive Remedy. Notwithstanding the above provisions regarding arbitration, the Parties each
retain their respective rights to seek injunctive relief or other provisional remedies provided under the law in any
court having competent jurisdiction.

5. NO ADMISSIONS

5.1. This Agreement represents a compromise and is being entered into to avoid costly litigation. By entering
into this Agreement, no Party hereto is admitting any liability or wrongdoing whatsoever, nor does this Agreement
constitute an admission of any fact, claim or allegation. This Agreement in no way implies the truth of any claim or
allegation. Furthermore, this Agreement shall not be construed as an admission that any Party violated any order, law,
statute, duty, contract, legal duty or obligation.

6. MISCELLANEOUS

6.1. Section 409A of the Code. No amount payable under this Agreement is intended to constitute or
provide for “nonqualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of
1986, as amended (“Section 409A”). If, however, at any time the Company determines that any amount payable under this
Agreement may be subject to Section 409A, the Company shall have the right, in its sole discretion, to adopt such
amendments to this Agreement or take such other actions (including amendments and

 

8

 

actions with retroactive effect) as the Company determines are necessary or appropriate to (a) exempt the amounts and
benefits provided hereunder from Section 409A and/or preserve the intended tax treatment of such amounts or benefits,
or (b) comply with the requirements of Section 409A and related Department of Treasury guidance.

6.2. Withholding. The Company may withhold from any amounts payable or benefits provided under this
Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable
law or regulation.

6.3. Severability. If any term, provision, covenant or condition of this Agreement is held by a court of
competent jurisdiction to exceed the limitations permitted by applicable law, then the provisions will be deemed
reformed to the maximum limitations permitted by applicable law and the Parties hereby expressly acknowledge their
desire that in such event such action be taken. Notwithstanding the foregoing, the Parties further agree that if any
provision of this Agreement or the application thereof to any person or circumstance shall be invalid or unenforceable
under any applicable law, such event shall not affect or render invalid or unenforceable any other provision of this
Agreement and shall not affect the application of any provision to other persons or circumstances.

6.4. Binding Agreement. This Agreement is personal to Bellantoni and without the prior written consent of
the Company shall not be assignable by Bellantoni otherwise than by will or the laws of descent and distribution. This
Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, permitted
assigns, heirs, executors and administrators.

6.5. Final and Entire Agreement. This Agreement represents the final and entire agreement among the
Parties with respect to the subject matter hereof and supersedes all prior agreements (including, without limitation,
the Employment Agreement other than Section 15 of the Employment Agreement), negotiations and discussions between the
Parties hereto and/or their respective counsel with respect to the subject matter hereof. Any amendment to this
Agreement must be in writing, and, except as set forth in Section 6.1, signed by duly authorized representatives of the
Parties.

6.6. Consultation with Counsel. Bellantoni acknowledges that (a) she has consulted with or has had the
opportunity to consult with independent counsel of her own choice concerning this Agreement and has been advised to do
so by the Company, and (b) she has read and understands the Agreement, is fully aware of its legal effect, and has
entered into it freely based on her own judgment.

6.7. Governing Law. The validity, interpretation, construction and performance of this Agreement shall be
governed by the laws of the United States where applicable and otherwise by the laws of the State of New Jersey.

6.8. Cooperation in Legal Proceedings. Bellantoni agrees that, after the Termination Date, upon the
reasonable request of the Company, she shall cooperate with and

 

9

 

assist the Company in undertaking and preparing for legal and other proceedings relating to the affairs of the Company
and its subsidiaries. Bellantoni shall be reimbursed for the reasonable expenses she incurs in connection with any
such cooperation and/or assistance, and shall receive from the Company reasonable per diem compensation in connection
therewith, as otherwise permitted by law.

6.9. Notices. For purposes of this Agreement, notices and all other communications provided for in this
Agreement shall be in writing and shall be deemed to have been duly given if hand-delivered, sent by documented
overnight delivery service or by certified or registered mail, return receipt requested, postage prepaid, addressed to
the respective addresses set forth below:

If to the Company:

Integra LifeSciences Holdings Corporation

311 Enterprise Drive

Plainsboro, New Jersey 08536

Attn: President

with a copy to:

The Company’s General Counsel

If to Bellantoni:

Maureen B. Bellantoni

or to such other address as either Party shall have furnished to the other in writing in accordance herewith. Notice
and communications shall be effective when actually received by the addressee.

6.10. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be an
original, but all of which taken together shall constitute one instrument.

[Signature Page Follows]

 

10

 

IN WITNESS WHEREOF, the parties hereto have each executed this Agreement as of the date first above written.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION,

a Delaware corporation

By: /s/ Stuart M. Essig      
Name: Stuart M. Essig

Title: President and Chief Executive Officer

MAUREEN B. BELLANTONI

/s/ Maureen B. Bellantoni     
Maureen B. Bellantoni

 

11

 

EXHIBIT A

GENERAL RELEASE

In exchange for the consideration set forth in that certain Separation Agreement, dated as of September 6, 2007,
between Integra LifeSciences Holdings Corporation (the “Company”) and the undersigned (the “Separation Agreement”), and
for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the undersigned
does hereby release and forever discharge the “Releasees” hereunder, consisting of the Company and each of its parents,
subsidiaries, affiliates, successors, partners, associates, heirs, assigns, agents, directors, officers, employees,
representatives, lawyers, insurers, and all persons acting by, through, under or in concert with them, or any of them,
of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts,
liens, contracts, agreements, promises, liability, claims, demands, damages, losses, costs, attorneys’ fees or
expenses, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which the
undersigned now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or
thing whatsoever from the beginning of time to the date hereof.  The Claims released herein include, without limiting
the generality of the foregoing, any Claims in any way arising out of, based upon, or related to the employment or
termination of employment of the undersigned by the Releasees, or any of them; any alleged breach of any express or
implied contract of employment; any alleged torts or other alleged legal restrictions on Releasee’s right to terminate
the employment of the undersigned; and any alleged violation of any federal, state or local statute or ordinance
including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the
Americans with Disabilities Act, the New Jersey Law Against Discrimination, the New Jersey Equal Pay Act and the New
Jersey Conscientious Employee Protection Act. Notwithstanding the foregoing, this Release shall not operate to release
any Claims which the undersigned may have to payments or benefits under Section 1.3 of the Separation Agreement.

IN ACCORDANCE WITH THE OLDER WORKERS BENEFIT PROTECTION ACT OF 1990, THE UNDERSIGNED IS HEREBY ADVISED AS FOLLOWS:

(A) SHE HAS THE RIGHT TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS RELEASE;

(B) SHE HAS TWENTY-ONE (21) DAYS TO CONSIDER THIS RELEASE BEFORE SIGNING IT; AND

(C) SHE HAS SEVEN (7) DAYS AFTER SIGNING THIS RELEASE TO REVOKE THIS RELEASE, AND THIS RELEASE WILL
BECOME EFFECTIVE UPON THE EXPIRATION OF THAT REVOCATION PERIOD.

The undersigned represents and warrants that there has been no assignment or other transfer of any interest in any
Claim which she may have against Releasees, or any of them, and the undersigned agrees to indemnify and hold Releasees,
and each of them, harmless

 

12

 

from any liability, Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of
them, as the result of any such assignment or transfer or any rights or Claims under any such assignment or transfer. 
It is the intention of the parties that this indemnity does not require payment as a condition precedent to recovery by
the Releasees against the undersigned under this indemnity.

The undersigned agrees that if she hereafter commences any suit arising out of, based upon, or relating to any of
the Claims released hereunder or in any manner asserts against Releasees, or any of them, any of the Claims released
hereunder, then the undersigned agrees to pay to Releasees, and each of them, in addition to any other damages caused
to Releasees thereby, all reasonable attorneys’ fees incurred by Releasees in defending or otherwise responding to said
suit or Claim.

The undersigned further understands and agrees that neither the payment of any sum of money nor the execution of
this Release shall constitute or be construed as an admission of any liability whatsoever by the Releasees, or any of
them.

The provisions of this Release are severable, and if any part of this Release is found to be unenforceable, the other
paragraphs (or portions thereof) shall remain fully valid and enforceable.

IN WITNESS WHEREOF, the undersigned has executed this Release as of this 6th day of September, 2007.

/s/ Maureen B. Bellantoni     
Maureen B. Bellantoni

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]